Richard Pops, Alkermes CEO (Patrick T. Fallon/Bloomberg via Getty Images)
November 17, 2020 07:32 AM ESTUpdated 07:59 AM
R&D
FDA+

Alk­er­mes is hand­ed a CRL for ‘3831, mark­ing an­oth­er set­back on the R&D front

John Carroll

Editor & Founder

Alk­er­mes $ALKS is go­ing to have to wait some more be­fore launch­ing its an­ti-psy­chot­ic com­bo drug ALKS-3831. The FDA has hand­ed the biotech a CRL …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times